Allogene Therapeutics (ALLO) Competitors $1.16 +0.07 (+6.42%) Closing price 05/20/2025 04:00 PM EasternExtended Trading$1.16 0.00 (-0.34%) As of 07:30 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ALLO vs. WVE, GYRE, PAHC, MLYS, COLL, SNDX, RCUS, ELVN, AVDL, and SYREShould you be buying Allogene Therapeutics stock or one of its competitors? The main competitors of Allogene Therapeutics include Wave Life Sciences (WVE), Gyre Therapeutics (GYRE), Phibro Animal Health (PAHC), Mineralys Therapeutics (MLYS), Collegium Pharmaceutical (COLL), Syndax Pharmaceuticals (SNDX), Arcus Biosciences (RCUS), Enliven Therapeutics (ELVN), Avadel Pharmaceuticals (AVDL), and Spyre Therapeutics (SYRE). These companies are all part of the "pharmaceutical products" industry. Allogene Therapeutics vs. Wave Life Sciences Gyre Therapeutics Phibro Animal Health Mineralys Therapeutics Collegium Pharmaceutical Syndax Pharmaceuticals Arcus Biosciences Enliven Therapeutics Avadel Pharmaceuticals Spyre Therapeutics Allogene Therapeutics (NASDAQ:ALLO) and Wave Life Sciences (NASDAQ:WVE) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, community ranking, valuation, media sentiment, analyst recommendations, profitability, dividends, institutional ownership and risk. Do institutionals and insiders hold more shares of ALLO or WVE? 83.6% of Allogene Therapeutics shares are held by institutional investors. Comparatively, 89.7% of Wave Life Sciences shares are held by institutional investors. 13.2% of Allogene Therapeutics shares are held by insiders. Comparatively, 29.1% of Wave Life Sciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Which has more risk & volatility, ALLO or WVE? Allogene Therapeutics has a beta of 0.6, suggesting that its stock price is 40% less volatile than the S&P 500. Comparatively, Wave Life Sciences has a beta of -0.92, suggesting that its stock price is 192% less volatile than the S&P 500. Does the media favor ALLO or WVE? In the previous week, Allogene Therapeutics had 9 more articles in the media than Wave Life Sciences. MarketBeat recorded 27 mentions for Allogene Therapeutics and 18 mentions for Wave Life Sciences. Wave Life Sciences' average media sentiment score of 1.12 beat Allogene Therapeutics' score of 0.04 indicating that Wave Life Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Allogene Therapeutics 4 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 7 Negative mention(s) 0 Very Negative mention(s) Neutral Wave Life Sciences 10 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is ALLO or WVE more profitable? Allogene Therapeutics has a net margin of 0.00% compared to Wave Life Sciences' net margin of -66.50%. Allogene Therapeutics' return on equity of -52.13% beat Wave Life Sciences' return on equity.Company Net Margins Return on Equity Return on Assets Allogene TherapeuticsN/A -52.13% -41.29% Wave Life Sciences -66.50%-280.57%-52.90% Which has higher valuation and earnings, ALLO or WVE? Wave Life Sciences has higher revenue and earnings than Allogene Therapeutics. Wave Life Sciences is trading at a lower price-to-earnings ratio than Allogene Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAllogene Therapeutics$22K11,533.09-$327.27M-$1.23-0.94Wave Life Sciences$104.94M9.61-$57.51M-$0.84-7.79 Do analysts prefer ALLO or WVE? Allogene Therapeutics currently has a consensus target price of $8.44, suggesting a potential upside of 627.97%. Wave Life Sciences has a consensus target price of $21.17, suggesting a potential upside of 223.65%. Given Allogene Therapeutics' higher probable upside, equities research analysts clearly believe Allogene Therapeutics is more favorable than Wave Life Sciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Allogene Therapeutics 0 Sell rating(s) 1 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.90Wave Life Sciences 0 Sell rating(s) 1 Hold rating(s) 10 Buy rating(s) 1 Strong Buy rating(s) 3.00 Does the MarketBeat Community believe in ALLO or WVE? Wave Life Sciences received 78 more outperform votes than Allogene Therapeutics when rated by MarketBeat users. Likewise, 67.77% of users gave Wave Life Sciences an outperform vote while only 66.21% of users gave Allogene Therapeutics an outperform vote. CompanyUnderperformOutperformAllogene TherapeuticsOutperform Votes29066.21% Underperform Votes14833.79% Wave Life SciencesOutperform Votes36867.77% Underperform Votes17532.23% SummaryWave Life Sciences beats Allogene Therapeutics on 11 of the 19 factors compared between the two stocks. Get Allogene Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ALLO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALLO vs. The Competition Export to ExcelMetricAllogene TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$253.73M$2.97B$5.43B$8.48BDividend YieldN/A1.72%5.22%4.11%P/E Ratio-0.7431.5826.8320.05Price / Sales11,533.09414.63392.35116.46Price / CashN/A168.6838.2534.62Price / Book0.383.376.874.61Net Income-$327.27M-$72.17M$3.22B$248.19M7 Day Performance21.75%18.10%6.76%2.97%1 Month Performance-18.31%20.85%13.66%16.58%1 Year Performance-56.88%-24.45%18.27%8.16% Allogene Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALLOAllogene Therapeutics3.6293 of 5 stars$1.16+6.4%$8.44+628.0%-55.2%$253.73M$22,000.00-0.74310Analyst RevisionGap UpWVEWave Life Sciences4.4236 of 5 stars$6.60+0.2%$21.17+220.7%+2.5%$1.02B$108.30M-5.95240Positive NewsGYREGyre Therapeutics0.2805 of 5 stars$10.83+13.6%N/A-21.0%$1.02B$105.76M541.5040PAHCPhibro Animal Health3.5524 of 5 stars$24.50+9.0%$20.00-18.4%+32.1%$992.32M$1.11B51.041,860Positive NewsMLYSMineralys Therapeutics2.78 of 5 stars$15.01+2.5%$33.00+119.9%+25.7%$973.79MN/A-4.1228Gap DownCOLLCollegium Pharmaceutical4.1231 of 5 stars$29.56+2.3%$43.80+48.2%-12.3%$949.82M$631.45M12.74210News CoverageGap UpSNDXSyndax Pharmaceuticals3.8938 of 5 stars$10.99+2.7%$35.91+226.7%-47.8%$945.66M$43.72M-3.03110Gap UpRCUSArcus Biosciences3.5953 of 5 stars$8.82+6.5%$25.67+191.2%-47.4%$933.38M$141M-2.80500Gap UpHigh Trading VolumeELVNEnliven Therapeutics2.5336 of 5 stars$19.01+3.2%$40.33+112.2%-27.6%$932.75MN/A-10.0150Earnings ReportAnalyst RevisionGap UpAVDLAvadel Pharmaceuticals2.2363 of 5 stars$9.59+2.1%$19.43+102.6%-40.3%$926.67M$169.12M-12.1470SYRESpyre Therapeutics2.3601 of 5 stars$14.93+5.9%$51.17+242.7%-58.2%$899.92M$890,000.00-2.00100Positive News Related Companies and Tools Related Companies WVE Competitors GYRE Competitors PAHC Competitors MLYS Competitors COLL Competitors SNDX Competitors RCUS Competitors ELVN Competitors AVDL Competitors SYRE Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ALLO) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Allogene Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Allogene Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ALLO Stock Free ALLO Stock Alerts